Tacrolimus-related encephalopathy following allogeneic stem cell transplantation in children

International Journal of Hematology

Volumn 81, Issue 3, 2005, Pages 264-268

  Kanekiyo, Takahisa ^a,b   Hara, Junichi ^a   Matsuda Hashii, Yoshiko ^a   Fujisaki, Hiroyuki ^a   Tokimasa, Sadao ^a   Sawada, Akihisa ^a   Kubota, Keiko ^a   Shimono, Kuriko ^a   Imai, Katsumi ^a   Ozono, Keiichi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Encephalopathy; Graft versus host disease; Hypertension; Tacrolimus

Indexed keywords

ANTIHYPERTENSIVE AGENT; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD PRESSURE REGULATION; BRAIN DISEASE; CEREBRAL BLINDNESS; CHILD; CLINICAL ARTICLE; CONVULSION; DROWSINESS; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG WITHDRAWAL; FEMALE; FLUID ATTENUATED INVERSION RECOVERY; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; MALE; NAUSEA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION WEIGHTED IMAGING; TECHNIQUE; WHITE MATTER; BLOOD DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PATHOPHYSIOLOGY; PRESCHOOL CHILD; TOXICITY AND INTOXICATION;

ANTIHYPERTENSIVE AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEUROTOXICITY SYNDROMES; TACROLIMUS;

EID: 20344384764     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.04162     Document Type: Article

References (21)

1. Yanik G, Levine JE, Ratanatharathorn V, Dunn R, Ferrara J, Hutchinson RJ. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation. Bone Marrow Transplant. 2000;26:161-167.
2. Tamaki H, Kawakami M, Ikegame K, et al. Successful treatment of tacrolimus (FK506)-related leukoencephalopathy with cerebral hemorrhage in a patient who underwent nonmyeloablative stem cell transplantation. Int J Hematol. 2004;80:291-294.
3. Devine SM, Newman NJ, Siegel JL, et al. Tacrolimus (FK506)-induced cerebral blindness following bone marrow transplantation. Bone Marrow Transplant. 1996;18:569-572.
4. Misawa A, Takeuchi Y, Hibi S, Todo S, Imashuku S, Sawada T. FK506-induced intractable leukoencephalopathy following allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000;25:331-334.
5. Grimbert P, Azema C, Pastural M, et al. Tacrolimus (FK506)-induced severe and late encephalopathy in a renal transplant recipient. Nephrol Dial Transplant. 1999;14:2489-2491.
6. Mori A, Tanaka J, Kobayashi S, et al. Fatal cerebral hemorrhage associated with cyclosporin-A/FK506-related encephalopathy after allogeneic bone marrow transplantation. Ann Hematol. 2000;79:588-592.
7. Furukawa M, Terae S, Chu BC, Kaneko K, Kamada H, Miyasaka K. MRI in seven cases of tacrolimus (FK-506) encephalopathy: utility of FLAIR and diffusion-weighted imaging. Neuroradiology. 2001; 43:615-621.
8. Teive HA, Brandi IV, Camargo CH, et al. Reversible posterior leucoencephalopathy syndrome associated with bone marrow transplantation. Arq Neuropsiquiatr. 2001;59:784-789.
9. Antonini G, Ceschin V, Morino S, et al. Early neurologic complications following allogeneic bone marrow transplant for leukemia: a prospective study. Neurology. 1998;50:1441-1445.
10. Faraci M, Lanino E, Dini G, et al. Severe neurologic complications after hematopoietic stem cell transplantation in children. Neurology. 2002;59:1895-1904.
11. Eidelman BH, Abu-Elmagd K, Wilson J, et al. Neurologic complications of FK 506. Transplant Proc. 1991;23:3175-3178.
12. de Brabander C, Cornelissen J, Smitt PA, Vecht CJ, van den Bent MJ. Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors. J Neurol Neurosurg Psychiatry. 2000;68:36-40.
13. Kochi S, Takanaga H, Matsuo H, et al. Induction of apoptosis in mouse brain capillary endothelial cells by cyclosporin A and tacrolimus. Life Sci. 2000;66:2255-2260.
14. Bleyer WA. Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep. 1981;65(suppl 1):89-98.
15. Yeager AM, Wagner JE Jr, Graham ML, Jones RJ, Santos GW, Grochow LB. Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood. 1992;80:2425-2428.
16. Zabernigg A, Maier H, Thaler J, Gattringer C. Late-onset fatal neurological toxicity of fludarabine. Lancet. 1994;344:1780.
17. Reece DE, Frei-Lahr DA, Shepherd JD, et al. Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin. Bone Marrow Transplant. 1991;8:393-401.
18. Matsuda Y, Hara J, Miyoshi H, et al. Thrombotic microangiopathy associated with reactivation of human herpesvirus-6 following high-dose chemotherapy with autologous bone marrow transplantation in young children. Bone Marrow Transplant. 1999;24:919-923.
19. Maslo C, Peraldi MN, Desenclos JC, et al. Thrombotic microangiopathy and cytomegalovirus disease in patients infected with human immunodeficiency virus. Clin Infect Dis. 1997;24:350-355.
20. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494-500.
21. Kaczmarek I, Groetzner J, Meiser B, et al. Impairment of the blood-brain barrier can result in tacrolimus-induced reversible leucoencephalopathy following heart transplantation. Clin Transplant. 2003;17:469-472.